CMT
MCID: CHR071
MIFTS: 64

Charcot-Marie-Tooth Disease (CMT)

Categories: Ear diseases, Eye diseases, Genetic diseases, Metabolic diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Charcot-Marie-Tooth Disease

MalaCards integrated aliases for Charcot-Marie-Tooth Disease:

Name: Charcot-Marie-Tooth Disease 11 19 42 52 75 28 53 5 41 14 38 71
Hereditary Motor and Sensory Neuropathy 19 42
Hmsn 19 42
Cmt 19 42
Pma 42 16
Charcot-Marie-Tooth Hereditary Neuropathy 42
Hereditary Motor and Sensory Neuropathies 71
Cmt - Charcot-Marie-Tooth Disease 11
Charcot-Marie-Tooth Syndrome 42
Charcot Marie Tooth Disease 19
Peroneal Muscular Atrophy 42

Classifications:



External Ids:

Disease Ontology 11 DOID:10595
ICD9CM 34 356.1
MeSH 43 D002607
NCIt 49 C75467
SNOMED-CT 68 193158000
ICD10 31 G60.0
UMLS 71 C0007959 C0027888

Summaries for Charcot-Marie-Tooth Disease

MedlinePlus Genetics: 42 Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. People with CMT2 may develop amyotrophic lateral sclerosis (ALS), a condition characterized by progressive muscle weakness, a loss of muscle mass, and an inability to control movement. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of  Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors).  Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.

MalaCards based summary: Charcot-Marie-Tooth Disease, also known as hereditary motor and sensory neuropathy, is related to charcot-marie-tooth disease, axonal, type 2e and charcot-marie-tooth disease and deafness, and has symptoms including back pain, headache and pain. An important gene associated with Charcot-Marie-Tooth Disease is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Neural crest differentiation and Intracellular trafficking proteins involved in CMT neuropathy. The drugs Folic acid and Lipoic acid have been mentioned in the context of this disorder. Affiliated tissues include Peripheral Nervous System, spinal cord and brain, and related phenotypes are no effect and no effect

MedlinePlus: 41 Charcot-Marie-Tooth disease (CMT) is a group of genetic nerve disorders. It is named after the three doctors who first identified it. In the United States, CMT affects about 1 in 2,500 people. CMT affects your peripheral nerves. Peripheral nerves carry movement and sensation signals between the brain and spinal cord and the rest of the body. Symptoms usually start around the teen years. Foot problems such as high arches or hammertoes can be early symptoms. As CMT progresses, your lower legs may weaken. Later, your hands may also become weak. Doctors diagnose CMT by doing a neurologic exam, nerve tests, genetic tests, or a nerve biopsy. There is no cure. The disease can be so mild you don't realize you have it or severe enough to make you weak. Physical therapy, occupational therapy, braces and other devices and sometimes surgery can help. NIH: National Institute of Neurological Disorders and Stroke

NINDS: 52 Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, and nearly all cases are inherited. CMT damages the body's peripheral nerves, making them unable to activate muscles or relay sensory informaton from the limbs back to the spinal cord and the brain. There are different types of CMT disease, which may share some symptoms but vary by pattern of inheritance and age of onset. Early symptoms typically include weakness or paralysis of the foot and lower leg muscles. As the disease progresses, weakness and decreased muscle bulk may occur in the hands, arms, legs, or feet. People may lose the ability to feel heat, cold, and touch. Chronic shortening of muscles or tendons around joints prevents the joints from moving freely, and muscle cramping is common. Some people have pain that can range from mild to severe. Genetic testing can detect the most common types of CMT.

GARD: 19 Charcot-Marie-Tooth disease is a group of disorders that affect the peripheral nerves, the nerves running from outside the brain and spine. Defects in many different genes cause different forms of this disease. Common symptoms may include foot drop, foot deformity, loss of lower leg muscle, numbness in the foot or leg, 'slapping" gait (feet hit the floor hard when walking), and weakness of the hips, legs, or feet.

Disease Ontology: 11 A neuromuscular disease that is characterized by a slowly progressive degeneration of the muscles of the foot, lower leg, hand and forearm.

Wikipedia: 75 Charcot-Marie-Tooth disease (CMT) is a hereditary motor and sensory neuropathy of the peripheral nervous... more...

Related Diseases for Charcot-Marie-Tooth Disease

Diseases in the Charcot-Marie-Tooth Disease family:

Charcot-Marie-Tooth Disease, Type 4a Charcot-Marie-Tooth Disease, Type 4b1
Charcot-Marie-Tooth Disease, Type 4d Charcot-Marie-Tooth Disease, Type 4c
Charcot-Marie-Tooth Disease, Type 4b2 Charcot-Marie-Tooth Disease, Dominant Intermediate B
Charcot-Marie-Tooth Disease, Dominant Intermediate D Charcot-Marie-Tooth Disease, Dominant Intermediate C
Charcot-Marie-Tooth Disease, Recessive Intermediate a Charcot-Marie-Tooth Disease, Type 4h
Charcot-Marie-Tooth Disease, Type 4j Charcot-Marie-Tooth Disease, Recessive Intermediate B
Charcot-Marie-Tooth Disease, Dominant Intermediate E Charcot-Marie-Tooth Disease, Dominant Intermediate F
Charcot-Marie-Tooth Disease, Type 4b3 Charcot-Marie-Tooth Disease, Recessive Intermediate C
Charcot-Marie-Tooth Disease, Recessive Intermediate D Charcot-Marie-Tooth Disease, Type 4k
Charcot-Marie-Tooth Disease, Dominant Intermediate G Charcot-Marie-Tooth Disease Type X
Charcot-Marie-Tooth Disease Intermediate Type Charcot-Marie-Tooth Disease Type 5
Charcot-Marie-Tooth Disease Type 7 Charcot-Marie-Tooth Disease Type 2a2a
Charcot-Marie-Tooth Disease Dominant Intermediate a Charcot-Marie-Tooth Disease Type 2a2b
Charcot-Marie-Tooth Disease Type 1g Autosomal Dominant Intermediate Charcot-Marie-Tooth
Autosomal Recessive Intermediate Charcot-Marie-Tooth Disease Charcot-Marie-Tooth Disease Type 2a
Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 Due to Kif5a Mutation Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 Due to Tfg Mutation
Dnajb2-Related Charcot-Marie-Tooth Disease Type 2 Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 Due to Dgat2 Mutation
Autosomal Dominant Charcot-Marie-Tooth Disease Type 2g

Diseases related to Charcot-Marie-Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 966)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2e 35.6 TRPV4 SPTLC1 SH3TC2 PRX PMP22 NEFL
2 charcot-marie-tooth disease and deafness 35.3 TRPV4 SPTLC1 SH3TC2 PRX PMP22 NEFL
3 neuropathy, congenital hypomyelinating, 1, autosomal recessive 35.2 TRPV4 SH3TC2 PRX PMP22 NEFL NDRG1
4 charcot-marie-tooth disease, demyelinating, type 1a 34.9 SPTLC1 SH3TC2 PRX PMP22 NEFL MPZ
5 charcot-marie-tooth disease, demyelinating, type 1b 34.9 SH3TC2 PRX PMP22 NEFL MPZ MFN2
6 charcot-marie-tooth disease, x-linked dominant, 1 34.9 SPTLC1 SH3TC2 PMP22 NEFL MPZ MFN2
7 hypertrophic neuropathy of dejerine-sottas 34.8 TRPV4 SH3TC2 PRX PMP22 NEFL NDRG1
8 charcot-marie-tooth disease, type 4b2 34.8 SH3TC2 PRX NEFL NDRG1 MPZ MFN2
9 charcot-marie-tooth disease, axonal, type 2b 34.7 SPTLC1 SH3TC2 NEFL MPZ MFN2 LITAF
10 charcot-marie-tooth disease, axonal, type 2f 34.7 NEFL MPZ MFN2 LITAF HSPB1 GJB1
11 tooth disease 34.7 TRPV4 SH3TC2 PRX PMP22 NEFL NDRG1
12 charcot-marie-tooth disease, axonal, type 2d 34.6 SH3TC2 NEFL MPZ MFN2 IGHMBP2 GJB1
13 charcot-marie-tooth disease, type 4a 34.6 SH3TC2 PRX MPZ MFN2 LITAF GJB1
14 charcot-marie-tooth disease, axonal, type 2b2 34.6 NEFL MPZ MFN2 LRSAM1 IGHMBP2 GDAP1
15 charcot-marie-tooth disease, type 4c 34.6 SH3TC2 NEFL NDRG1 MPZ MFN2 LITAF
16 charcot-marie-tooth disease, type 4h 34.6 SH3TC2 PRX NDRG1 MPZ LITAF GJB1
17 charcot-marie-tooth disease, demyelinating, type 1d 34.6 PRX PMP22 NEFL NDRG1 MPZ LITAF
18 charcot-marie-tooth disease, demyelinating, type 4f 34.6 SH3TC2 PRX MPZ LITAF GJB1 GDAP1
19 charcot-marie-tooth disease, axonal, type 2i 34.6 SH3TC2 PRX NEFL MPZ MFN2 GJB1
20 charcot-marie-tooth disease, demyelinating, type 1c 34.6 SH3TC2 PRX PMP22 MPZ LITAF GJB1
21 hereditary motor and sensory neuropathy, type iic 34.5 TRPV4 SH3TC2 NEFL MPZ MFN2 GJB1
22 charcot-marie-tooth disease, axonal, type 2l 34.5 NEFL MPZ MFN2 HSPB1 GDAP1 GARS1
23 charcot-marie-tooth disease, type 4b1 34.5 SH3TC2 PRX MPZ LITAF GDAP1 FIG4
24 charcot-marie-tooth disease, demyelinating, type 1f 34.5 SH3TC2 PMP22 NEFL MPZ LITAF GJB1
25 charcot-marie-tooth disease, axonal, type 2a1 34.5 MPZ MFN2 LRSAM1 GDAP1 GARS1 AARS1
26 charcot-marie-tooth disease, type 4d 34.4 SH3TC2 NDRG1 MPZ LITAF GJB1 GDAP1
27 charcot-marie-tooth disease, axonal, type 2j 34.4 SH3TC2 PRX NEFL MPZ GJB1 GDAP1
28 charcot-marie-tooth disease, type 4j 34.4 SH3TC2 MPZ LITAF GJB1 GDAP1 FIG4
29 charcot-marie-tooth disease, dominant intermediate b 34.4 SH3TC2 MPZ LITAF GJB1 GDAP1
30 charcot-marie-tooth disease, axonal, type 2p 34.3 SH3TC2 MPZ LRSAM1 LITAF GDAP1
31 charcot-marie-tooth disease, axonal, type 2n 34.3 MPZ MFN2 GDAP1 GARS1 AARS1
32 charcot-marie-tooth disease, dominant intermediate c 34.2 SPTLC1 MPZ GJB1 GDAP1 GARS1 AARS1
33 charcot-marie-tooth disease, axonal, type 2t 34.2 SH3TC2 LRSAM1 IGHMBP2 GDAP1
34 charcot-marie-tooth disease, axonal, type 2b1 34.2 LMNA IGHMBP2 GDAP1
35 charcot-marie-tooth disease, type 4b3 34.2 SH3TC2 PMP22 MPZ LITAF FIG4
36 charcot-marie-tooth disease intermediate type 34.2 SH3TC2 MPZ MFN2 GJB1 GDAP1 GARS1
37 neuropathy, hereditary motor and sensory, russe type 34.2 SH3TC2 NDRG1 GDAP1 FIG4
38 charcot-marie-tooth disease type x 34.2 SPTLC1 SH3TC2 PMP22 NEFL MPZ MFN2
39 charcot-marie-tooth disease, axonal, type 2r 34.1 LRSAM1 IGHMBP2 GDAP1
40 charcot-marie-tooth disease, recessive intermediate a 34.1 MFN2 GJB1 GDAP1
41 charcot-marie-tooth disease, dominant intermediate e 34.1 SH3TC2 MPZ GDAP1
42 charcot-marie-tooth disease, dominant intermediate d 34.0 MPZ MFN2 GJB1
43 charcot-marie-tooth disease dominant intermediate a 34.0 SH3TC2 PRX MPZ GJB1 GDAP1
44 charcot-marie-tooth disease, x-linked recessive, 2 34.0 MPZ LITAF GJB1
45 hereditary sensory neuropathy 34.0 SPTLC1 SH3TC2 MPZ GDAP1
46 neuropathy 34.0 TRPV4 SPTLC1 SH3TC2 PRX PMP22 NEFL
47 neuropathy, hereditary, with liability to pressure palsies 33.9 SH3TC2 PRX PMP22 NEFL NDRG1 MPZ
48 charcot-marie-tooth disease, axonal, type 2u 33.9 GARS1 AARS1
49 charcot-marie-tooth disease, recessive intermediate d 33.9 LRSAM1 GDAP1
50 charcot-marie-tooth disease, axonal, type 2w 33.9 GARS1 AARS1

Graphical network of the top 20 diseases related to Charcot-Marie-Tooth Disease:



Diseases related to Charcot-Marie-Tooth Disease

Symptoms & Phenotypes for Charcot-Marie-Tooth Disease

UMLS symptoms related to Charcot-Marie-Tooth Disease:


back pain; headache; pain; sciatica; seizures; syncope; tremor; chronic pain; vertigo/dizziness; sleeplessness

GenomeRNAi Phenotypes related to Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 AARS1 FIG4 GARS1 GDAP1 GJB1 HSPB1
2 no effect GR00402-S-2 10.17 AARS1 FIG4 GDAP1 HSPB1 IGHMBP2 LITAF

MGI Mouse Phenotypes related to Charcot-Marie-Tooth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.36 AARS1 FIG4 GARS1 GDAP1 GJB1 IGHMBP2
2 homeostasis/metabolism MP:0005376 10.22 AARS1 GARS1 GDAP1 GJB1 HSPB1 IGHMBP2
3 behavior/neurological MP:0005386 10.11 AARS1 FIG4 GARS1 GDAP1 GJB1 IGHMBP2
4 muscle MP:0005369 10.07 AARS1 FIG4 GARS1 IGHMBP2 LMNA MFN2
5 cardiovascular system MP:0005385 9.96 AARS1 FIG4 HSPB1 IGHMBP2 LMNA MFN2
6 vision/eye MP:0005391 9.61 GARS1 GJB1 IGHMBP2 LMNA NDRG1 PMP22
7 integument MP:0010771 9.28 AARS1 FIG4 GARS1 GDAP1 IGHMBP2 LMNA

Drugs & Therapeutics for Charcot-Marie-Tooth Disease

Drugs for Charcot-Marie-Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
2
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1077-27-6, 1200-22-2 864 445125 6112
3 Micronutrients Phase 4
4 Folate Phase 4
5 Vitamins Phase 4
6 Trace Elements Phase 4
7 Vitamin B9 Phase 4
8 Vitamin B Complex Phase 4
9 Protective Agents Phase 4
10 Antioxidants Phase 4
11 Alpha-lipoic Acid Phase 4
12
Acetylcarnitine Approved, Investigational Phase 2, Phase 3 3040-38-8
13
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
14
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
15
Baclofen Approved Phase 3 1134-47-0 2284
16
Ethanol Approved Phase 3 64-17-5 702
17
Ascorbic acid Approved, Nutraceutical Phase 2, Phase 3 50-81-7 54676860 54670067 5785
18
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 2, Phase 3 461-06-3
19 Nootropic Agents Phase 2, Phase 3
20 Pharmaceutical Solutions Phase 3
21 Gastrointestinal Agents Phase 3
22 Narcotics Phase 3
23 GABA Agonists Phase 3
24 Narcotic Antagonists Phase 3
25 Cathartics Phase 3
26 Laxatives Phase 3
27 Neurotransmitter Agents Phase 3
28 Hematinics Phase 2, Phase 3
29
Epoetin Alfa Phase 2, Phase 3
30 Neuroprotective Agents Phase 2, Phase 3
31
Mexiletine Approved, Investigational Phase 2 5370-01-4, 31828-71-4 4178
32
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 253 171548
33
Ubidecarenone Approved, Investigational, Nutraceutical Phase 1, Phase 2 303-98-0 5281915
34 Vitamin B7 Phase 2
35 Ubiquinone Phase 1, Phase 2
36
Ulipristal acetate Phase 2 126784-99-4 13559282 130904
37
Iron Approved 7439-89-6 29936
38
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
39
Tannic acid Approved 1401-55-4 16129878 16129778
40
Ropivacaine Approved 84057-95-4 71273 175805
41
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
42
Cholecalciferol Approved, Nutraceutical, Vet_approved 67-97-0, 1406-16-2 5280795 10883523
43
Chitosan low molecular weight (20-200 mpa.s) Experimental 14257-69-3, 9012-76-4 441477 71853
44 Analgesics
45 Calcium, Dietary
46 Calciferol
47
Insulin
48 Insulin, Globin Zinc
49 Immunosuppressive Agents
50 Immunologic Factors

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
2 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
3 A Multicenter Study to Evaluate the Effects on Charcot-Marie-Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. Unknown status NCT01289704 Phase 2, Phase 3
4 International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months Completed NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
5 A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
6 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
7 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months Recruiting NCT05092841 Phase 3 PXT3003;PXT3003 placebo
8 International, Multi-center, Open Label, Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Active, not recruiting NCT03023540 Phase 3 PXT3003
9 A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Active, not recruiting NCT04762758 Phase 3 (RS)-baclofen, naltrexone hydrochloride and D-sorbitol;Placebo
10 Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
11 The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study Unknown status NCT01562860 Phase 2
12 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
13 Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) Completed NCT05361031 Phase 1, Phase 2
14 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
15 A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A. Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
16 Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
17 Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A Completed NCT00271635 Phase 2 Placebo;ascorbic acid
18 Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study Completed NCT00634738 Phase 1, Phase 2
19 Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) Suspended NCT03520751 Phase 1, Phase 2 scAAV1.tMCK.NTF3
20 A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease Terminated NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
21 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X Terminated NCT03124459 Phase 2 ACE-083;Placebo
22 An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 Terminated NCT03943290 Phase 2 ACE-083
23 LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
24 Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A Recruiting NCT05333406 Phase 1 EN001
25 Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study Unknown status NCT03550300
26 Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT Unknown status NCT02979145
27 The Feasibility and Effect of Ankle Foot Orthoses and Underfoot Vibration on the Postural Stability of People With Inherited Neuropathy Unknown status NCT03278093
28 Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs Unknown status NCT01918826
29 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
30 BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease Completed NCT02982343
31 Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients Completed NCT02001038
32 Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease Completed NCT01455623
33 Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Completed NCT01750710
34 Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Completed NCT02011204
35 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
36 An Open Observational Study of Clinical and Electrophysiological Outcomes in Male and Female Patients With CMT Type 1 & 2, and Aged-matched Healthy Controls Completed NCT04980807
37 Clinical and Genetic Features of Familial Neuropathy Completed NCT00149045
38 A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care Completed NCT03715283
39 Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) Completed NCT02194010
40 Influence of Irisin on Muscle Quality in a Cohort of Charcot-Marie-Tooth Patients Completed NCT04786522
41 Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies Completed NCT02788734
42 An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients Completed NCT02429947
43 Biomarkers and Validation of Selected Outcome Measures (CMTNSmod) Completed NCT03386266
44 Accuracy of Ultrasonography and Electromyography in the Diagnosis of Carpal Tunnel Syndrome Completed NCT02553811
45 The Effect of Ulnar Nerve Injury Localization on Sleep Quality in Patients With Ulnar Nerve Entrapment Neuropathy Completed NCT05177861
46 Clinical Outcomes of Surgical Release Among Diabetic Patients With Carpal Tunnel Syndrome. A Prospective Study With Matched Controls Completed NCT00775333
47 The Management of Abdominal Cutaneous Nerve Entrapment Syndrome Completed NCT03574727
48 Posterior Interosseous Nerve Pathology May Provide Novel Insights Into Both Predisposition and Potential Vascular Basis for the Development of Carpal Tunnel Syndrome in Diabetic Patients. Completed NCT00856011
49 Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory Completed NCT03062722
50 Analysis of Pain and Quality of Life in Patients With Charcot-Marie-Tooth Neuropathy (CMT) Completed NCT03966287

Search NIH Clinical Center for Charcot-Marie-Tooth Disease

Genetic Tests for Charcot-Marie-Tooth Disease

Genetic tests related to Charcot-Marie-Tooth Disease:

# Genetic test Affiliating Genes
1 Charcot-Marie-Tooth Disease 28 CNTNAP1 DCTN2 DRP2 MCM3AP MORC2 SGPL1 WARS1

Anatomical Context for Charcot-Marie-Tooth Disease

Organs/tissues related to Charcot-Marie-Tooth Disease:

MalaCards : Spinal Cord, Brain, Tonsil, Skeletal Muscle, Dorsal Root Ganglion, Skin, Temporal Lobe
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Charcot-Marie-Tooth Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Affected by disease

Publications for Charcot-Marie-Tooth Disease

Articles related to Charcot-Marie-Tooth Disease:

(show top 50) (show all 4355)
# Title Authors PMID Year
1
Increased monomerization of mutant HSPB1 leads to protein hyperactivity in Charcot-Marie-Tooth neuropathy. 53 62 5
20178975 2010
2
Clinical, electrophysiological and molecular genetic studies in a family with X-linked dominant Charcot-Marie-Tooth neuropathy presenting a novel mutation in GJB1 Promoter and a rare polymorphism in LITAF/SIMPLE. 53 62 5
16373087 2006
3
Connexin32 and X-linked Charcot-Marie-Tooth disease. 53 62 5
9361298 1997
4
Copy number variations in a population-based study of Charcot-Marie-Tooth disease. 62 5
25648254 2015
5
The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. 62 5
25614874 2014
6
Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next-generation sequencing. 62 5
25025039 2014
7
Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. 62 5
22933740 2012
8
[Clinical-genetic characteristics of hereditary motor-sensory neuropathy type 1 X]. 62 5
23011429 2012
9
Genetic spectrum of hereditary neuropathies with onset in the first year of life. 62 5
21840889 2011
10
Characterizing the phenotypic manifestations of MFN2 R104W mutation in Charcot-Marie-Tooth type 2. 62 5
21531138 2011
11
Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy. 62 5
20660910 2010
12
The phenotype of Charcot-Marie-Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. 62 5
19272779 2009
13
MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. 53 5
16714318 2006
14
Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. 62 5
15122254 2004
15
Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. 62 5
14574644 2003
16
Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. 62 5
12402337 2002
17
Diverse trafficking abnormalities of connexin32 mutants causing CMTX. 62 5
12460545 2002
18
HINT1 neuropathy in Lithuania: clinical, genetic, and functional profiling. 62 41
36242072 2022
19
Magnetic resonance imaging-based lower limb muscle evaluation in Charcot-Marie-Tooth disease type 1A patients and its correlation with clinical data. 62 41
36198750 2022
20
Small heat-shock protein HSPB1 mutants stabilize microtubules in Charcot-Marie-Tooth neuropathy. 5
22031878 2011
21
Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations. 5
18425620 2008
22
Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. 5
18478590 2008
23
Founder SH3TC2 mutations are responsible for a CMT4C French-Canadians cluster. 5
18511281 2008
24
Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. 5
16924012 2006
25
Congenital cataract facial dysmorphism neuropathy syndrome: a clinically recognizable entity. 5
16194727 2005
26
Recording cutaneous silent period parameters in hereditary and acquired neuropathies. 41
36252592 2022
27
Adult onset Charcot-Marie-Tooth disease type 1D with an Arg381Cys mutation of EGR2. 53 62
20513111 2010
28
Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. 53 62
20418531 2010
29
Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease. 53 62
19888301 2010
30
Dynamin 2 and human diseases. 53 62
20127478 2010
31
Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults. 53 62
20163430 2010
32
Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. 53 62
20037586 2010
33
Six new gap junction beta 1 gene mutations and their phenotypic expression in Czech patients with Charcot-Marie-Tooth disease. 53 62
20039784 2010
34
Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation. 53 62
19932620 2010
35
Charcot-Marie-Tooth type 1A disease caused by a novel Ser112Arg mutation in the PMP22 gene, coexisting with a slowly progressive hearing impairment. 53 62
20453308 2010
36
YY1-dependent transcriptional regulation of the human GDAP1 gene. 53 62
19720140 2009
37
[Mutation analysis of MFN2 gene in Chinese patients with Charcot-Marie-Tooth disease]. 53 62
20193559 2009
38
[Two novel mutations of GJB1 gene associated with typical X-linked Charcot-Marie-Tooth disease]. 53 62
20193560 2009
39
GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. 53 62
19782751 2009
40
Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. 53 62
20008656 2009
41
Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. 53 62
19923170 2009
42
Identification and in silico analysis of 14 novel GJB1, MPZ and PMP22 gene mutations. 53 62
19259128 2009
43
Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. 53 62
19293842 2009
44
Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. 53 62
19427854 2009
45
Novel mutations in the GDAP1 gene in patients affected with early-onset axonal Charcot-Marie-Tooth type 4A. 53 62
19500985 2009
46
PMP22 expression in dermal nerve myelin from patients with CMT1A. 53 62
19447823 2009
47
Functional and comparative genomics analyses of pmp22 in medaka fish. 53 62
19534778 2009
48
Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K). 53 62
19089472 2009
49
A laminin-2, dystroglycan, utrophin axis is required for compartmentalization and elongation of myelin segments. 53 62
19321787 2009
50
[Ultrastructural lesions of axonal mitochondria in patients with childhood-onset Charcot-Marie-Tooth disease due to MFN2 mutations]. 53 62
19718987 2009

Variations for Charcot-Marie-Tooth Disease

ClinVar genetic disease variations for Charcot-Marie-Tooth Disease:

5 (show top 50) (show all 3058)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MFN2 NM_014874.4(MFN2):c.1392+1G>A SNV Pathogenic
637063 rs1569861708 GRCh37: 1:12064671-12064671
GRCh38: 1:12004614-12004614
2 GJB1 NM_000166.6(GJB1):c.576del (p.Phe193fs) DEL Pathogenic
637162 rs1602349692 GRCh37: X:70444133-70444133
GRCh38: X:71224283-71224283
3 GJB1 NM_000166.6(GJB1):c.629_632del (p.Val210fs) DEL Pathogenic
637163 rs1602349779 GRCh37: X:70444186-70444189
GRCh38: X:71224336-71224339
4 GJB1 NM_000166.6(GJB1):c.800del (p.Pro267fs) DEL Pathogenic
637165 rs1602350003 GRCh37: X:70444355-70444355
GRCh38: X:71224505-71224505
5 GJB1 NM_000166.6(GJB1):c.822del (p.Glu275fs) DEL Pathogenic
637166 rs1602350029 GRCh37: X:70444379-70444379
GRCh38: X:71224529-71224529
6 GJB1 NM_000166.6(GJB1):c.844dup (p.Ala282fs) DUP Pathogenic
637167 rs1602350062 GRCh37: X:70444399-70444400
GRCh38: X:71224549-71224550
7 GJB1 NM_000166.6(GJB1):c.381C>G (p.Ile127Met) SNV Pathogenic
637216 rs1602349264 GRCh37: X:70443938-70443938
GRCh38: X:71224088-71224088
8 HSPB1 NM_001540.5(HSPB1):c.505del (p.Met169fs) DEL Pathogenic
637259 rs1583966508 GRCh37: 7:75933377-75933377
GRCh38: 7:76304060-76304060
9 GJB1 NM_000166.6(GJB1):c.785_786del (p.Ile262fs) DEL Pathogenic
637234 rs1602349962 GRCh37: X:70444341-70444342
GRCh38: X:71224491-71224492
10 PMP22 NM_000304.4(PMP22):c.256C>T (p.Gln86Ter) SNV Pathogenic
637389 rs11545341 GRCh37: 17:15142851-15142851
GRCh38: 17:15239534-15239534
11 PRX NM_181882.3(PRX):c.1173del (p.Arg392fs) DEL Pathogenic
637391 rs757771239 GRCh37: 19:40903086-40903086
GRCh38: 19:40397179-40397179
12 PRX NM_181882.3(PRX):c.124_125dup (p.Phe43fs) DUP Pathogenic
637392 rs1599662837 GRCh37: 19:40909671-40909672
GRCh38: 19:40403764-40403765
13 SH3TC2 NM_024577.4(SH3TC2):c.524del (p.Gln175fs) DEL Pathogenic
631961 rs1561770179 GRCh37: 5:148422262-148422262
GRCh38: 5:149042699-149042699
14 SH3TC2 NM_024577.4(SH3TC2):c.688del (p.Val230fs) DEL Pathogenic
637409 rs775740308 GRCh37: 5:148421022-148421022
GRCh38: 5:149041459-149041459
15 SH3TC2 NM_024577.4(SH3TC2):c.957del (p.Phe320fs) DEL Pathogenic
448371 rs1554122541 GRCh37: 5:148417902-148417902
GRCh38: 5:149038339-149038339
16 MFN2 NM_014874.4(MFN2):c.751C>G (p.Pro251Ala) SNV Pathogenic
2272 rs28940295 GRCh37: 1:12059087-12059087
GRCh38: 1:11999030-11999030
17 GDAP1 NM_018972.4(GDAP1):c.928del (p.Arg310fs) DEL Pathogenic
637555 rs1586807541 GRCh37: 8:75276452-75276452
GRCh38: 8:74364217-74364217
18 PMP22 NM_000304.4(PMP22):c.179-2A>G SNV Pathogenic
637829 rs1597608225 GRCh37: 17:15142930-15142930
GRCh38: 17:15239613-15239613
19 MPZ NM_000530.8(MPZ):c.646-10_650del DEL Pathogenic
217234 rs863225026 GRCh37: 1:161275763-161275777
GRCh38: 1:161305973-161305987
20 MPZ NM_000530.8(MPZ):c.574_575del (p.Arg192fs) MICROSAT Pathogenic
637320 rs1571817911 GRCh37: 1:161276128-161276129
GRCh38: 1:161306338-161306339
21 GDAP1 NM_018972.4(GDAP1):c.1A>T (p.Met1Leu) SNV Pathogenic
637503 rs1474390668 GRCh37: 8:75262697-75262697
GRCh38: 8:74350462-74350462
22 GDAP1 NM_018972.4(GDAP1):c.501del (p.Glu168fs) DEL Pathogenic
280104 rs886041386 GRCh37: 8:75274135-75274135
GRCh38: 8:74361900-74361900
23 HSPB1 NM_001540.5(HSPB1):c.171_172insGCGCCCT (p.Leu58fs) INSERT Pathogenic
637505 rs1583964560 GRCh37: 7:75932200-75932201
GRCh38: 7:76302883-76302884
24 MPZ NM_000530.8(MPZ):c.197G>A (p.Trp66Ter) SNV Pathogenic
637507 rs1571819946 GRCh37: 1:161277085-161277085
GRCh38: 1:161307295-161307295
25 MPZ NM_000530.8(MPZ):c.204C>A (p.Tyr68Ter) SNV Pathogenic
637508 rs1571819906 GRCh37: 1:161277078-161277078
GRCh38: 1:161307288-161307288
26 SH3TC2 NM_024577.4(SH3TC2):c.1384G>T (p.Glu462Ter) SNV Pathogenic
234623 rs749850181 GRCh37: 5:148407911-148407911
GRCh38: 5:149028348-149028348
27 MPZ NM_000530.8(MPZ):c.68-5_71del DEL Pathogenic
637769 rs1571820401 GRCh37: 1:161277211-161277219
GRCh38: 1:161307421-161307429
28 MPZ NM_000530.8(MPZ):c.560del (p.Gln187fs) DEL Pathogenic
637770 rs1571817966 GRCh37: 1:161276143-161276143
GRCh38: 1:161306353-161306353
29 PMP22 NM_000304.4(PMP22):c.76del (p.Ser26fs) DEL Pathogenic
637827 rs1597635540 GRCh37: 17:15163969-15163969
GRCh38: 17:15260652-15260652
30 PMP22 NM_000304.4(PMP22):c.138del (p.Ser47fs) DEL Pathogenic
219616 rs864622180 GRCh37: 17:15162451-15162451
GRCh38: 17:15259134-15259134
31 NEFL NM_006158.5(NEFL):c.1039_1040del (p.Met347fs) DEL Pathogenic
916802 rs1803032912 GRCh37: 8:24812990-24812991
GRCh38: 8:24955476-24955477
32 PRX NM_181882.3(PRX):c.124_125insGCTGC (p.Ile42fs) INSERT Pathogenic
916817 rs2079512634 GRCh37: 19:40909672-40909673
GRCh38: 19:40403765-40403766
33 SH3TC2 NM_024577.4(SH3TC2):c.2489_2492del (p.Glu830fs) MICROSAT Pathogenic
916840 rs80338929 GRCh37: 5:148406803-148406806
GRCh38: 5:149027240-149027243
34 SH3TC2 NM_024577.4(SH3TC2):c.2095C>T (p.Gln699Ter) SNV Pathogenic
916841 rs1754094644 GRCh37: 5:148407200-148407200
GRCh38: 5:149027637-149027637
35 FIG4 NM_014845.6(FIG4):c.1801del (p.Thr601fs) DEL Pathogenic
916867 rs1777638564 GRCh37: 6:110098175-110098175
GRCh38: 6:109776972-109776972
36 FIG4 NM_014845.6(FIG4):c.2247dup (p.Ser750fs) DUP Pathogenic
916868 rs767193357 GRCh37: 6:110112639-110112640
GRCh38: 6:109791436-109791437
37 NDRG1 NM_006096.4(NDRG1):c.681dup (p.Ile228fs) DUP Pathogenic
246500 rs879254290 GRCh37: 8:134262699-134262700
GRCh38: 8:133250456-133250457
38 TTR NM_000371.4(TTR):c.148G>C (p.Val50Leu) SNV Pathogenic
Pathogenic
13440 rs28933979 GRCh37: 18:29172937-29172937
GRCh38: 18:31592974-31592974
39 MPZ NM_000530.8(MPZ):c.303G>A (p.Trp101Ter) SNV Pathogenic
Uncertain Significance
586153 rs1558154149 GRCh37: 1:161276643-161276643
GRCh38: 1:161306853-161306853
40 MPZ NM_000530.8(MPZ):c.200_201del (p.Arg67fs) MICROSAT Pathogenic
917144 rs1670284480 GRCh37: 1:161277081-161277082
GRCh38: 1:161307291-161307292
41 PMP22 NM_000304.4(PMP22):c.327C>A (p.Cys109Ter) SNV Pathogenic
217237 rs863225028 GRCh37: 17:15134390-15134390
GRCh38: 17:15231073-15231073
42 PMP22 NM_000304.4(PMP22):c.433del (p.Leu145fs) DEL Pathogenic
586346 rs1567698872 GRCh37: 17:15134284-15134284
GRCh38: 17:15230967-15230967
43 HSPB1 NM_001540.5(HSPB1):c.153G>A (p.Trp51Ter) SNV Pathogenic
917325 rs769118115 GRCh37: 7:75932182-75932182
GRCh38: 7:76302865-76302865
44 SH3TC2 NM_024577.4(SH3TC2):c.2989del (p.Arg997fs) DEL Pathogenic
637410 rs1174949678 GRCh37: 5:148406199-148406199
GRCh38: 5:149026636-149026636
45 GDAP1 NM_018972.4(GDAP1):c.1019dup (p.Arg341fs) DUP Pathogenic
406140 rs756461496 GRCh37: 8:75276540-75276541
GRCh38: 8:74364305-74364306
46 GDAP1 NM_018972.4(GDAP1):c.579+1G>A SNV Pathogenic
220379 rs864622501 GRCh37: 8:75274214-75274214
GRCh38: 8:74361979-74361979
47 GJB1 NM_000166.6(GJB1):c.64C>T (p.Arg22Ter) SNV Pathogenic
Uncertain Significance
447441 rs1555937020 GRCh37: X:70443621-70443621
GRCh38: X:71223771-71223771
48 GARS1 NM_002047.4(GARS1):c.1031+1G>A SNV Pathogenic
637502 rs1554338272 GRCh37: 7:30651862-30651862
GRCh38: 7:30612246-30612246
49 MPZ NM_000530.8(MPZ):c.256C>T (p.Gln86Ter) SNV Pathogenic
462792 rs1553259703 GRCh37: 1:161276690-161276690
GRCh38: 1:161306900-161306900
50 NEFL NM_006158.5(NEFL):c.1261C>T (p.Arg421Ter) SNV Pathogenic
192322 rs191346286 GRCh37: 8:24811218-24811218
GRCh38: 8:24953704-24953704

Copy number variations for Charcot-Marie-Tooth Disease from CNVD:

6 (show all 19)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15789 1 11962824 11996159 Copy number MFN2 Charcot-marie-tooth disease
2 16677 1 129927668 130016331 Copy number RAB7A Charcot-marie-tooth disease
3 21558 1 159541148 159546386 Copy number MPZ Charcot-marie-tooth disease
4 44856 10 64241762 64248933 Copy number EGR2 Charcot-marie-tooth disease
5 61129 11 95205693 95297019 Copy number MTMR2 Charcot-marie-tooth disease
6 63372 12 118100977 118116934 Copy number HSPB8 Charcot-marie-tooth disease
7 64536 12 129300000 133851895 Heterozygous duplication PMP22 Charcot-marie-tooth disease
8 97625 16 11549356 11588823 Copy number LITAF Charcot-marie-tooth disease
9 106965 17 10700000 16000000 Duplication PMP22 Charcot-marie-tooth disease
10 107010 17 11200000 22100000 Duplication,deletion PMP22 Charcot-marie-tooth disease
11 107372 17 15073820 15109369 Copy number PMP22 Charcot-marie-tooth disease
12 107373 17 15073820 15109369 Deletion PMP22 Charcot-marie-tooth disease
13 107542 17 15900000 22100000 Microdeletion Charcot-marie-tooth disease
14 109385 17 25800000 31800000 Amplification PMP22 Charcot-marie-tooth disease
15 195048 5 147909892 148422930 Copy number SH3TC2 Charcot-marie-tooth disease
16 228313 7 75769858 75771546 Copy number HSPB1 Charcot-marie-tooth disease
17 237596 8 24864385 24870043 Copy number NEFL Charcot-marie-tooth disease
18 242862 8 75425172 75441890 Copy number GDAP1 Charcot-marie-tooth disease
19 264803 X 70351786 70361777 Copy number GJB1 Charcot-marie-tooth disease

Expression for Charcot-Marie-Tooth Disease

Search GEO for disease gene expression data for Charcot-Marie-Tooth Disease.

Pathways for Charcot-Marie-Tooth Disease

Pathways related to Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.34 PMP22 MPZ GJB1
2 10.79 SH3TC2 PMP22 NEFL NDRG1 MPZ MFN2
3 10.58 PRX PMP22 MPZ

GO Terms for Charcot-Marie-Tooth Disease

Biological processes related to Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelination GO:0042552 9.46 PMP22 MPZ FIG4
2 myelin assembly GO:0032288 9.26 PMP22 FIG4
3 peripheral nervous system myelin maintenance GO:0032287 9.1 SH3TC2 PRX NDRG1

Molecular functions related to Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 TTR TRPV4 NEFL LMNA LITAF IGHMBP2

Sources for Charcot-Marie-Tooth Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....